Skip to main content

Advertisement

Table 1 Characteristics of the study patients before and after propensity score matching

From: Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction

Variable Before matching After matching
Statin (n = 611) Non-statin (n = 1370) P value Statin (n = 441) Non-statin (n = 441) P value
Age (year) 64.6 ± 10.2 67.5 ± 10.1 <.001 65.8 ± 10.2 65.6 ± 10.1 .844
Age group (years)    <.001    .933
 21–60 210 (34.4) 324 (23.6)   131 (29.7) 136 (30.8)  
 61–80 365 (59.7) 891 (65.0)   276 (62.6) 271 (61.5)  
 > 80 36 (5.9) 155 (11.3)   34 (7.7) 34 (7.7)  
Gender    .038    .636
 Male 323 (52.9) 793 (57.9)   236 (53.5) 243 (55.1)  
 Female 288 (47.1) 577 (42.1)   205 (46.5) 198 (44.9)  
Dialysis    .033    1.000
 Hemodialysis 558 (91.3) 1287 (93.9)   402 (91.2) 402 (91.2)  
 Peritoneal dialysis 53 (8.7) 83 (6.1)   39 (8.8) 39 (8.8)  
Dialysis duration (year) 3.1 ± 2.9 3.1 ± 3.1 .949 3.3 ± 3.0 3.3 ± 3.3 .860
Diabetes mellitus duration (year) 11.3 ± 3.4 10.1 ± 3.8 <.001 11.2 ± 3.3 11.3 ± 3.4 .563
Comorbidity
 Hypertension 512 (83.8) 1045 (76.3) <.001 367 (83.2) 363 (82.3) .721
 Dyslipidemia 428 (70.0) 412 (30.1) <.001 259 (58.7) 254 (57.6) .733
 Heart failure 347 (56.8) 640 (46.7) <.001 231 (52.4) 230 (52.2) .946
 Old myocardial infarction 209 (34.2) 505 (36.9) .256 156 (35.4) 141 (32.0) .285
 Atrial fibrillation 49 (8.0) 113 (8.2) .864 35 (7.9) 33 (7.5) .801
 Peripheral arterial disease 99 (16.2) 228 (16.6) .808 69 (15.6) 70 (15.9) .926
 Chronic obstructive pulmonary disease 42 (6.9) 110 (8.0) .372 30 (6.8) 29 (6.6) .893
 Malignancy 45 (7.4) 107 (7.8) .731 33 (7.5) 34 (7.7) .899
 Cirrhosis 6 (1.0) 46 (3.4) .002 6 (1.4) 6 (1.4) 1.000
 Gout 43 (7.0) 90 (6.6) .700 28 (6.3) 33 (7.5) .507
Previous PCI 201 (32.9) 385 (28.1) .031 143 (32.4) 136 (30.8) .612
Previous CABG 49 (8.0) 97 (7.1) .460 33 (7.5) 32 (7.3) .897
Old ischemic stroke 172 (28.2) 420 (30.7) .260 124 (28.1) 130 (29.5) .655
Old hemorrhage stroke 16 (2.6) 33 (2.4) .781 12 (2.7) 10 (2.3) .666
History of bleeding (major bleeding) 308 (50.4) 693 (50.6) .943 227 (51.5) 223 (50.6) .788
Medication
 Aspirin 429 (70.2) 648 (47.3) <.001 287 (65.1) 291 (66.0) .777
 Clopidogrel 494 (80.9) 670 (48.9) <.001 338 (76.6) 331 (75.1) .582
 Warfarin 12 (2.0) 15 (1.1) .123 11 (2.5) 9 (2.0) .651
 ACEI/ARB 343 (56.1) 481 (35.1) <.001 220 (49.9) 226 (51.2) .686
 β-blocker 370 (60.6) 487 (35.5) <.001 239 (54.2) 225 (51.0) .345
 Sulfonylurea 122 (20.0) 189 (13.8) <.001 91 (20.6) 86 (19.5) .674
 Thiazolidinediones 13 (2.1) 38 (2.8) .402 12 (2.7) 11 (2.5) .833
 Insulin 276 (45.2) 472 (34.5) <.001 185 (42.0) 177 (40.1) .584
  1. ACEi/ARB angiotensin-converting-enzyme inhibitor/angiotensin receptor blockers, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention